5-Year Outcomes After Left Atrial Appendage Closure From the PREVAIL and PROTECT AF Trials

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F12%3A00007391" target="_blank" >RIV/00023884:_____/12:00007391 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.jacc.2017.10.021" target="_blank" >http://dx.doi.org/10.1016/j.jacc.2017.10.021</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jacc.2017.10.021" target="_blank" >10.1016/j.jacc.2017.10.021</a>

Result language
angličtina
Original language name
5-Year Outcomes After Left Atrial Appendage Closure From the PREVAIL and PROTECT AF Trials
Original language description
The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, St. Paul, Minnesota) was equivalent to warfarin for preventing stroke in atrial fibrillation, but had a high rate of complications. In a second randomized trial, PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy), the complication rate was low. The warfarin cohort experienced an unexpectedly low ischemic stroke rate, rendering the efficacy endpoints inconclusive. However, these outcomes were based on relatively few patients followed for a relatively short time.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)